Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cross-reactivity

Cross-reactivity

Conservation of Declining Populations

Conservation of Declining Populations

Conservation of declining population focuses on ways of detecting, diagnosing, and halting a population decline. The approach uses methods to prevent populations from going extinct.

Vaccinations

Vaccinations

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Conservation of Small Populations

Conservation of Small Populations

Small population sizes put a species at extreme risk of extinction due to a lack of variation, and a consequent decrease in adaptability. This weakens the chances of survival under pressures such as climate change, competition from other species, or new diseases. Large populations are more likely to survive pressures such as these, as such populations are more likely to harbor individuals that have genetic variants that are adaptive under new stresses. Small populations are much less...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Chikungunya virus virus-like particle vaccine (VIMKUNYA) elicits cross-neutralization across CHIKV lineages and against other alphaviruses after just one dose.

Vaccine·2026

Same author

Chikungunya virus virus-like particle vaccine (Vimkunya) induces a rapid and durable antigen-specific CD4<sup>+</sup> T cell response.

Vaccine·2026

Same author

A chikungunya virus-like particle vaccine reduces chikungunya disease in cynomolgus macaques and protection is mediated by antibody transferred from vaccinated humans.

NPJ vaccines·2026

Same author

Passive transfer of human sera from chikungunya virus virus-like particle vaccine (Vimkunya) recipients fully protects non-human primates from viremia.

NPJ vaccines·2026

Same author

Identification of the seven critical residues that control ZIKV-DENV cross-reactivity to engineer a non-cross-reactive ZIKV vaccine.

Cell reports·2025

Same author

How Rwanda mounted a research response with an investigational vaccine just ten days into a Marburg outbreak.

NPJ vaccines·2025

Search research articles

Related Experiment Video

Updated: Apr 28, 2026

Preparation and Gene Modification of Nonhuman Primate Hematopoietic Stem and Progenitor Cells

Preparation and Gene Modification of Nonhuman Primate Hematopoietic Stem and Progenitor Cells

Published on: February 15, 2019

Vaccinating captive chimpanzees to save wild chimpanzees.

Kelly L Warfield¹, Jason E Goetzmann², Julia E Biggins³

¹Integrated BioTherapeutics, Inc., Gaithersburg, MD 20878;

Proceedings of the National Academy of Sciences of the United States of America

|June 10, 2014

Summary

Vaccines for endangered apes are safe and effective. This study tested an Ebola virus vaccine in captive chimpanzees, showing it is safe and prompts an immune response, offering hope for wild ape conservation.

Keywords:

conservation filovirus wildlife disease

More Related Videos

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity

Published on: June 25, 2015

A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses

A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses

Published on: August 31, 2014

Related Experiment Videos

Last Updated: Apr 28, 2026

Preparation and Gene Modification of Nonhuman Primate Hematopoietic Stem and Progenitor Cells

Preparation and Gene Modification of Nonhuman Primate Hematopoietic Stem and Progenitor Cells

Published on: February 15, 2019

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity

Published on: June 25, 2015

A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses

A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses

Published on: August 31, 2014

Area of Science:

Primate Conservation Biology
Veterinary Vaccinology
Wildlife Disease Ecology

Background:

Infectious diseases pose a significant threat to the survival of endangered chimpanzees and critically endangered gorillas.
Vaccination has not been widely used in wild ape populations due to concerns regarding vaccine safety and efficacy.
Ebola virus is a primary cause of mortality in wild gorillas and chimpanzees.

Purpose of the Study:

To evaluate the safety and immunogenicity of a virus-like particle vaccine against Ebola virus in captive chimpanzees.
To assess the potential of using captive great apes as a model for testing vaccines intended for wild ape populations.
To explore vaccination as a tool to combat infectious disease threats to endangered ape species.

Main Methods:

A virus-like particle vaccine targeting Ebola virus was administered to captive chimpanzees.
Vaccine safety was monitored through clinical observations and health assessments.
Immunogenicity was assessed by measuring the immune response generated by the vaccine.

Main Results:

The Ebola virus vaccine was found to be safe for use in captive chimpanzees.
The vaccine successfully elicited an immune response, demonstrating immunogenicity.
No adverse effects were observed in the vaccinated chimpanzee subjects.

Conclusions:

Captive chimpanzees can serve as a reliable model for testing vaccines for wild ape populations.
This Ebola virus vaccine is a promising candidate for protecting wild gorillas and chimpanzees from this deadly disease.
Further captive trials of vaccines and delivery methods are crucial for developing strategies to prevent wild ape extinction.